Clinical Trial News and Research

RSS

TauRx initiates LMTX Phase 3 trial in Pick's Disease

TauRx Therapeutics today announced the initiation of a global Phase 3 clinical trial in a type of Frontotemporal Dementia (FTD) also known as Pick's Disease. The announcement, which immediately follows The 8th International Conference on Frontotemporal Dementias, held 5-7 September in Manchester, England, underscores the need for new treatments for this form of dementia that is similar to Alzheimer's Disease, except that it tends to damage different areas of the brain and affects people as early as 40 years old.

10 Sep 2012

Baylor Health Care System raises awareness about atrial fibrillation

An estimated 2.5 million Americans suffer from irregular heartbeats-also known as atrial fibrillation. Baylor Health Care System is raising awareness about this often misunderstood, but potentially life changing cardiovascular condition whose incidence is on the rise and expected to more than double by 2050.

10 Sep 2012

Cedars-Sinai receives CIRM grant to continue study of stem cell therapy for heart disease

A team of Cedars-Sinai Heart Institute stem cell researchers today was awarded a $1.3 million grant from the California Institute of Regenerative Medicine to continue study of an experimental stem cell therapy that treats heart attack patients with heart-derived cells. Earlier this year, data from the first clinical trial of the stem cell treatment showed the therapy helped damaged hearts regrow healthy muscle.

10 Sep 2012

Enrollment complete in DOUBle Phase 3 clinical trial of AzaSite Plus and DexaSite for blepharitis

InSite Vision Incorporated today announced that patient enrollment has been completed in the DOUBle Phase 3 clinical trial of AzaSite Plus (ISV-502) and DexaSite (ISV-305) for the treatment of blepharitis.

7 Sep 2012

CIRM awards Cedars-Sinai $1.3M to study stem cell therapy for heart attacks

7 Sep 2012

Biopsies may misdiagnose eosinophilic esophagitis

University of Utah engineers mapped white blood cells called eonsinophils and showed an existing diagnostic method may overlook an elusive digestive disorder that causes swelling in the esophagus and painful swallowing.

7 Sep 2012

RSV virus selectively kills cancer cells

RSV, a virus that causes respiratory infections in infants and young children, selectively kills cancer cells while leaving healthy cells alone, researchers from the School of Medicine at The University of Texas Health Science Center San Antonio said.

7 Sep 2012

The Institute of Cancer Research, CRT and Astex to discover and develop novel drug candidates

Astex Pharmaceuticals, Inc, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, Cancer Research Technology Limited (CRT) and The Institute of Cancer Research, London, have initiated a collaboration to discover and develop drug candidates targeting an undisclosed epigenetic target in a blood cancer with high unmet medical need.

7 Sep 2012

Durata completes target enrollment in dalbavancin Phase 3 trials for abSSSI

Durata Therapeutics today announced that it has completed its target enrollment for DISCOVER 1 ("Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response"), one of two ongoing, global, Phase 3 clinical trials of Durata's lead product candidate, dalbavancin, under investigation for the treatment of acute bacterial skin and skin structure infections (abSSSI).

7 Sep 2012

Vitamin D supplements have unintended lipid consequences

Correcting vitamin D levels in individuals at risk for cardiovascular disease may have detrimental effects on their lipid profiles, report researchers.

6 Sep 2012

Omeros files OMS824 IND with FDA to initiate clinical trials for cognitive disorders

Omeros Corporation today announced that it has filed an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) to initiate clinical trials evaluating OMS824, the Company's lead compound from its phosphodiesterase 10 (PDE10) program for schizophrenia and other cognitive disorders.

6 Sep 2012

Clinical trial to test combination of two drugs in treating fibromyalgia

A chronic pain condition and numerous gastrointestinal disorders may all be caused by a virus. That's a Tuscaloosa-based surgeon's theory likely headed for a clinical trial early next year and one drawing support from a University of Alabama researcher who studies how viruses replicate.

6 Sep 2012

FDA continues review of Salix’s Crofelemer new drug application

Napo Pharmaceuticals, Inc. was informed today that the Food and Drug Administration is continuing its review of the new drug application seeking approval of crofelemer for the treatment of chronic diarrhea in people living with HIV/AIDS on anti-retroviral therapy.

6 Sep 2012

Baxter commences anti-MIF antibody Phase I trial in malignant solid tumors

Baxter International Inc. today announced that the company has begun dosing patients with malignant solid tumors in a Phase I clinical trial of a monoclonal antibody, representing the company's efforts to extend its oncology portfolio with advanced biological research and development.

From Baxter International Inc. 6 Sep 2012

ImmunoCellular completes enrollment in ICT-107 Phase II trial for glioblastoma

ImmunoCellular Therapeutics, Ltd. announced today that the company has completed enrollment for its Phase II randomized, double-blinded, placebo-controlled, multi-center trial of its dendritic cell-based cancer vaccine ICT-107 for treatment of glioblastoma.

6 Sep 2012

Two UNC autism researchers receive $12.6 million in grants from ACE program

Two autism researchers in the University of North Carolina School of Medicine have each been awarded $12.6 million grants in the latest round of funding from the National Institutes of Health's Autism Centers of Excellence (ACE) research program.

6 Sep 2012

Study questions use of vitamin D supplements to improve cholesterol

Vitamin D has been touted for its beneficial effects on a range of human systems, from enhancing bone health to reducing the risk of developing certain cancers. But it does not improve cholesterol levels, according to a new study conducted at The Rockefeller University Hospital.

From Quest Diagnostics 5 Sep 2012

People need to protect themselves against West Nile virus

As this year's threat from the West Nile virus continues, one infectious diseases expert at the University of Alabama at Birmingham says a vaccine is not in our near future, so people need to protect themselves.

5 Sep 2012

NeuroSigma's external Trigeminal Nerve Stimulation system awarded CE Certification

NeuroSigma, Inc., a Los Angeles-based medical device company, announced today that it received CE Certification for its external Trigeminal Nerve Stimulation (eTNS) system, called the Monarch, for the adjunctive treatment of epilepsy and major depressive disorder, for adults and children 9 years and older.

5 Sep 2012

NCI awards Soligenix $300,000 SBIR grant for orBec Phase 2 chronic GI GVHD trial

Soligenix, Inc., a development stage biopharmaceutical company, announced today that the National Cancer Institute has awarded Soligenix a Small Business Innovation Research grant to support the conduct of a Phase 2 clinical trial designed to evaluate orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestation of chronic Graft-versus-Host disease.

5 Sep 2012